Hírek

Alaunos buys Velaris, raises $350m for lung drugs

The Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029. Alaunos Therapeutics, based in Fort Lauderdale, has an obesity program at the center of how it describes itself. That program is ALN1003, an oral small molecule the company calls a non-hormonal, non-incretin approach. On 13 […] The post Alaunos buys Velaris, raises $350m for lung drugs appeared first on Longevity.Technology.

L-Nutra Health launches metabolic programme to UK clinics

L-Nutra Health has launched a clinician-led metabolic health programme in the United Kingdom, making it available to clinics and medical practices for the first time. The programme is built on more than 25 years of research led by Dr Valter Longo and centres on the Fasting Mimicking Diet, which the company claims is a patented, […] The post L-Nutra Health launches metabolic programme to UK clinics appeared first on Longevity.Technology.

Mitochondrien: Wenn die Kraftwerke der Zellen stottern

Eine neue Theorie verbindet zahlreiche Volkskrankheiten über den Energiestoffwechsel.

Immunis wins grand prize for novel anti-aging stem cell therapy

Immunis has been awarded the Grand Prize in the National Academy of Medicine’s Healthy Longevity Global Competition for IMM01-STEM, an investigational multi-active biologic the company claims can address interconnected biological processes underlying age-related muscle and metabolic decline. The 2026 Grand Prize was open exclusively to prior Healthy Longevity Catalyst Award recipients; from 2020 to 2025 […] The post Immunis wins grand prize for novel anti-aging stem cell therapy appeared first on Longevity.Technology.

Fractyl shifts focus to Revita weight-maintenance procedure following successful trial

Fractyl is concentrating financial and operational resources on Revita after positive six-month topline results from the REMAIN-1 pivotal cohort, which met its prespecified six-month co-primary endpoint with high statistical significance (p=0.0023). The company claims Revita could become the first durable procedural therapy for post-GLP-1 weight maintenance. The company plans an FDA de novo submission in […] The post Fractyl shifts focus to Revita weight-maintenance procedure following successful trial appeared first on Longevity.Technology.

Mind the gap: pregnancy, recovery and the aging clock

A new review argues postpartum recovery may shape lifelong aging; a fandom health standard asks who helps mothers get there. Pregnancy ages a woman – measurably, if not necessarily permanently. The more interesting question, according to a new review in Trends in Endocrinology & Metabolism, is what happens afterwards. The authors, Stephen Albright and Jesse […] The post Mind the gap: pregnancy, recovery and the aging clock appeared first on Longevity.Technology.

Amylin drug cuts weight up to 9.2% in diabetes trial

Zealand Pharma’s petrelintide delivered up to 9.2% weight loss over 28 weeks in people with obesity and type 2 diabetes, with few dropouts. Here is the figure that jumped out first. Just 1.9% of people taking petrelintide in a new Phase 2 trial stopped because of stomach-related side effects. In the placebo group, it was […] The post Amylin drug cuts weight up to 9.2% in diabetes trial appeared first on Longevity.Technology.

PLA2G2F is Protective of Memory Function in the Aging Brain

Researchers here identify the gene PLA2G2F as a regulator of compensatory responses to some of the damage and dysfunction of aging. The researchers were primarily investigating a population of neurons found in the hippocampus, involved in memory function, but find that the gene is relevant in supporting cells of the brain also, such as microglia. Expression of PLA2G2F increases with age, and artificially increasing expression over natural levels produces greater protection. PLA2G2F appears to be involved in maintenance of normal lipid metabolism. Evidence suggests that dysfunctions in lipid metabolism occur in the aging brain, and cause harm via provoking greater inflammatory behavior in a number of supporting cell populations. Cognitive reserve theory posits that compensatory mechanisms during aging stave off cognitive decline and lower risk […]

The APOEε4 Variant Interferes in Myelination in the Aging Brain

Of the common variants of the APOE gene, APOEε4 presents the greatest risk of Alzheimer's disease. APOE is involved in lipid metabolism, and APOEε4 is associated with lipid-related contributions to inflammation in microglia, suggesting a primarily inflammatory mechanism for the increased risk of neurodegeneration. Here, researchers find that APOEε4 also interferes in the ability of oligodendrocyte cells to maintain the myelin structures that sheath the axons that connect neurons into neural networks, again via lipid-related mechanisms. This myelin sheathing is required for effective communication between neurons. Myelin maintenance does falter to some degree in normal aging, and the consequent loss of myelin is thought to contribute to dysfunction in the aging brain. It is reasonable to hypothesize that greater myelin loss driven by APOEε4 is […]

Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases

The gut–brain axis has emerged as a central mechanistic framework linking dietary bioactives, microbial ecology, and neurodegenerative disease progression. Similar microbiome-related mechanisms have also been implicated in colorectal cancer, suggesting potential shared links between microbial dysbiosis, inflammation, and disease progression. This study synthesizes preclinical evidence examining how polyphenols, polyphenol-derived compounds, and advanced delivery systems, including nanoparticles and synbiotics, modulate Alzheimer’s disease (AD) and Parkinson’s disease (PD) through microbiome-dependent mechanisms. Evidence from transgenic mice, toxin-induced rodent models, and Drosophila systems was compared across microbiome alterations, microbial metabolites, signaling pathways, epigenetic regulation, and functional outcomes. Across AD and PD models, dietary bioactives consistently promo

Microbial metabolites as modulators of gut–brain communication in neurodegeneration: from intestinal sensing to disease initiation and progression

How heterogeneous gut metabolite alterations relate to Parkinson’s disease (PD) and Alzheimer’s disease (AD) remains unresolved. We propose a framework in which intestinal sensing of indole derivatives, short-chain fatty acids and bile acids links microbial function to barrier regulation and gut–brain communication. Integration denotes tissue-level convergence of aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR) and metabolite-responsive G-protein-coupled receptor responses across epithelial and neighbouring immune cells, rather than an established same-cell receptor complex. Tryptophan metabolism provides an analytical focus connecting microbial indole production with host kynurenine and serotonin pathways; metabolite concentrations alone do not establish pathway flux or receptor activity. We hypothesise that suppressed indole-associated epithelial signalling, barrier hyperperm

Giving birth again too soon after having a baby could lead to quicker biological aging

The study of biological aging, how our cells, tissues and organs change over time, independent of how many years have passed, is a growing area of research that aims to help scientists understand the root causes of chronic illnesses and find ways to enhance longevity. A review article published in Trends in Endocrinology & Metabolism discusses the connections between pregnancy and biological aging.

Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal

Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly $1.2b in milestones. Zealand Pharma has been a peptide company for more than 25 years, and now the Copenhagen outfit is asking an AI specialist to help it branch into proteins. The announcement came on 13 October. Zealand […] The post Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal appeared first on Longevity.Technology.

Natural compound could fight rheumatoid arthritis at its source

A natural compound extracted from a medicinal plant has shown surprising promise against rheumatoid arthritis. In rats, it reduced joint swelling, protected cartilage, and calmed the immune responses responsible for chronic inflammation. Scientists discovered that the compound works by targeting a specific protein and restoring balance to fatty acid metabolism, revealing a previously underexplored way to fight the disease.

Italian lab to test cell capsules for diabetes

Avaí Bio and Austrianova began work with Ospedale San Raffaele on protecting lab-grown insulin cells from the immune system. Nobody in diabetes research is short of ambition. The dream of swapping out the insulin-making cells the body has lost has been around for a long time, and so has its biggest obstacle. Transplanted cells get […] The post Italian lab to test cell capsules for diabetes appeared first on Longevity.Technology.

Omada Health to present research on weight loss during GLP-1 therapy

Omada Health will present peer-reviewed research at the World Obesity and Weight Management Congress in Boston showing that members of its GLP-1 Care Track lost more weight and improved body composition more than GLP-1 users receiving usual care. The findings, published in Diabetes, Obesity and Metabolism, followed 245 adults who began a GLP-1 within the […] The post Omada Health to present research on weight loss during GLP-1 therapy appeared first on Longevity.Technology.

Rivus to present data on new oral weight-loss drug that targets fat while saving muscle

Rivus Pharmaceuticals will present preclinical nonhuman primate and rodent data for RV-8451 at ObesityWeek 2026, with three poster presentations scheduled for 14-15 November in Washington, D.C. Poster abstracts announced by the company include a head-to-head comparison in obesity models in which RV-8451 outperforms orforglipron, a study showing RV-8451 reverses orforglipron-induced lean mass loss in a […] The post Rivus to present data on new oral weight-loss drug that targets fat while saving muscle appeared first on Longevity.Technology.

Evidence for Peroxisome Dysfunction to be Important in Alzheimer's Disease is Not Conclusive

Peroxisomes in cells are responsible for helping to maintain oxidative metabolism via making and removing hydrogen peroxide, but are also involved in numerous aspects of lipid metabolism, breaking down or converting various lipids necessary to cell function. They have other, less well mapped functions relating to defense against pathogens. There is some evidence for peroxisome loss to occur with age, for this to be a meaningful cause of further cellular dysfunction. As researchers note here, however, the evidence for forms of peroxisome dysfunction to contribute meaningfully to Alzheimer's disease is suggestive but far from conclusive. As is often the case, the fastest path to clarity would be an approach to restore a more youthful peroxisome function to cells in the brain and elsewhere, and see […]

Cellular Senescence in Liver Aging

Senescent cells accumulate with age, perhaps primarily because the aged immune system becomes less able to efficiently destroy senescent cells as it does in youth. When a cell becomes senescent it ceases to replicate, grows in size, and secretes a potent mix of pro-inflammatory, pro-growth signals that contribute to the chronic inflammation of aging and are disruptive to tissue structure and function. Here, researchers investigate some of the specific outcomes of an increased burden of cellular senescence in the aged liver. The liver is organized into tightly regulated zones with distinct metabolic functions but zonation erodes with age. Cellular senescence contributes to aging and liver diseases, however, its impact on aging biology is ill-defined. As part of The Cellular Senescence Network Consortium, we used multiple […]

Sub-$60 DEXA body scans open in Oakland

BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes. Your bathroom scale is a bit of a liar by omission. It’ll tell you that you’ve lost eight pounds and keep quiet about whether those pounds were fat, muscle or something else. BodySpec’s CEO and co-founder […] The post Sub-$60 DEXA body scans open in Oakland appeared first on Longevity.Technology.

29% of long-term GLP-1 users lack nutrient confidence

A Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand. Everybody seems to be Googling GLP-1 lately. Searches for the term ran 120% higher over the past year than the year before, according to Google Trends data cited in a new UK report. Plenty of […] The post 29% of long-term GLP-1 users lack nutrient confidence appeared first on Longevity.Technology.

Predicting Inflammation and Disease Risk with Gut Microbiome Composition

The gut microbiome changes with age, and evidence suggests that this provides a meaningful contribution to degeneration and disease. Microbial populations that provoke chronic inflammation grow in size at the expense of populations that produce beneficial metabolites. Researchers here show that gut microbiome composition is a better predictor of the burden of inflammation and risk of disease than chronological age, much as one might expect given what is known of age-related changes in gut microbiome composition, and also given that researchers have built aging clocks from gut microbiome data. It is one more argument for a greater focus on the development and availability of therapeutic approaches capable of lasting rejuvenation of the gut microbiome, such as fecal microbiota transplantation and flagellin immunization. Low-grade systemic inflammation […]

Fractyl Revita reduces post-GLP-1 weight regain in pivotal study

Fractyl Health reported positive six-month topline results from the REMAIN-1 pivotal cohort, a randomized, double-blind, sham-controlled study of the Revita DMR System in adults with obesity after tirzepatide-induced weight loss. According to the company, in the modified intention-to-treat population (N=308) Revita participants maintained approximately 80% of their glp-1–induced weight loss at six months versus 67% […] The post Fractyl Revita reduces post-GLP-1 weight regain in pivotal study appeared first on Longevity.Technology.

Physical exercise: a multi-target strategy for the prevention and treatment of Alzheimer’s disease

Alzheimer’s disease (AD) is a devastating age-related neurodegenerative disease characterized by irreversible cognitive dysfunction and neuronal loss. The complex pathogenesis of AD involves core proteinopathies of amyloid-β (Aβ) and tau, chronic neuroinflammation, and extensive cerebral metabolic disorders, which collectively drive progressive neuronal damage and disease deterioration. Currently, effective disease-modifying drugs for AD are still lacking, and physical exercise has been recognized as a safe and effective non-pharmacological intervention to prevent and alleviate AD pathological progression. Specifically, exercise inhibits abnormal Aβ deposition and tau hyperphosphorylation, suppresses microglial overactivation and sustained neuroinflammatory responses, and remodels cerebral metabolic homeostasis by improving glucose utilization, balancing lactate metabolism, restoring mit

Scientists discover how deep sleep builds muscle, burns fat, and boosts the brain

Scientists have discovered a surprising two-way relationship between sleep and growth hormone, revealing how the brain carefully balances physical recovery with wakefulness. The findings could help explain why poor sleep harms metabolism and brain health, potentially opening the door to new treatments for sleep and neurological disorders.

Kailera’s obesity trials are full, results due 2028

All three Phase 3 trials of the weekly shot ribupatide have finished enrolling, and the head-to-head against semaglutide is the one to watch. Roughly 4,900 people have now signed up to spend about a year and a half testing a weekly obesity injection, and most of us won’t hear how it went until the middle […] The post Kailera’s obesity trials are full, results due 2028 appeared first on Longevity.Technology.

Heart pill cuts inflammation markers in early trial

Monte Rosa’s NEK7-targeting drug pulled several heart-risk biomarkers toward healthy levels in 108 people with obesity. Think of NLRP3 as a fire alarm wired into your immune cells. When it trips, cells burst open and spill out a cocktail of inflammatory signals. That response is handy during an infection. In the walls of diseased arteries, […] The post Heart pill cuts inflammation markers in early trial appeared first on Longevity.Technology.

Digbi Health expands precision biology care nationwide

Digbi Health expanded its precision biology telehealth platform to all 50 states through collaborations with OpenLoop Health and MD Integrations, giving members of more than 300 employers and health plans access to over 700 physicians, nurse practitioners and coaches. The company says members can receive GLP-1 medications and hormone replacement therapy as part of a […] The post Digbi Health expands precision biology care nationwide appeared first on Longevity.Technology.

Interaction of sex and insulin resistance with cognitive impairment in community-dwelling middle-aged and older adults

IntroductionCognitive impairment is a major global health challenge. However, whether sex and age interactively varies the association between insulin resistance and cognitive impairment remains unclear. This cross-sectional study aimed to evaluate the association between insulin resistance and cognitive impairment and identify sex- and age-specific interactions in community-dwelling adults.MethodsThe study involved 3,898 participants (aged 54–86 years) from the Ansan-Ansung cohort of the Korean Genome and Epidemiology Study (2017–2018). Insulin resistance was assessed via Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), with participants dichotomized by the median (1.97). Cognitive impairment was defined as a score of ≤23 on the Korean Mini-Mental State Examination score. Multivariable logistic regression was applied to examine the interaction and stratified effects of sex

Hypertensive stress rewires macrophage signaling in heart failure with preserved ejection fraction independent of obesity

Interactions of the Gut Microbiome and Exercise in the Context of Muscle Aging Leading to Frailty

Animal studies suggest that the composition and activities of the gut microbiome are as influential on long-term health and the progression of degenerative aging as is the case for lifestyle choices such as degree of physical fitness and level of physical activity. The gut microbiome changes with age: microbial populations delivering harmful metabolites or that otherwise provoke the immune system into a state of chronic inflammation grow in number, while microbial populations delivering beneficial metabolites necessary for tissue function are reduced in number. Rejuvenation of the gut microbiome, which can be achieved via fecal microbiota transplantation from a young donor to old recipient, has been shown to improve health and extend life in aged animals. In the matters of health and aging, untangling the contribution […]

Sironax Phase 2 trial reaches half enrollment for SIR4156 obesity study

Sironax said on 13 October that it has reached about 50 percent of its targeted patient enrollment in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator being evaluated in combination with semaglutide in adults with obesity. The double-blind, randomized, placebo-controlled, parallel-group study aims to assess SIR4156’s effect on body […] The post Sironax Phase 2 trial reaches half enrollment for SIR4156 obesity study appeared first on Longevity.Technology.

Menopausal Serum Protein Changes May Predict Brain Health

A recent analysis of serum protein changes identified 16 proteins related to inflammatory, synaptic, metabolic, and Alzheimer’s disease processes whose levels change during the menopausal transition [1]. These changes were linked to cognitive health later […]

Atrogi’s muscle pill shows early promise in 13 people

Small open-label study of ATR-258 saw fat loss, lean mass gains and better leg power, but no placebo group and just eight weeks long. Losing weight on the new wave of obesity drugs often comes with a side order of lost muscle. Studies suggest that 25–45% of the weight lost on incretin-based medicines may be […] The post Atrogi’s muscle pill shows early promise in 13 people appeared first on Longevity.Technology.

Typ-2-Diabetes: GLP-1-RA und SGLT-2-Hemmer könnten nur bei Albuminurie nephroprotektiv wirken

Boston – Die nephroprotektive Wirkung von GLP-1-Rezeptoragonisten (GLP-1-RA) und SGLT-2-Hemmern bei Menschen mit Typ-2-Diabetes, auf die randomisierte Studien hinweisen, könnte den Ergebnissen einer aktuellen Analyse zufolge auf Personen mit Albuminurie beschränkt sein ( BMJ 2026; DOI: 10.1136/bmj-2026-100574). Die nephroprotektive Wirkung von...[weiter lesen]

miR-128-3p Inhibition Improves Muscle Mass and Function in Aged Mice

That the calorie restriction imposed by GLP-1 receptor agonists induces loss of muscle mass has proved a boon for research into ways to address the loss of muscle mass that occurs with age, contributing to frailty. Suddenly a relatively large amount of funding and industry attention is available for programs that might result in a drug to prevent muscle loss in GLP-1 receptor agonist patients, and most of those options can at least in principle be used to treat age-related muscle loss. Here, researchers demonstrate a novel approach to inducing muscle growth in aged mice, by inhibiting a relevant microRNA; the technology is developed by Elenae Therapeutics which, as is usual, targets more severe and less common indications at the outset, such as improving outcomes […]

A clinical prediction model for 90-day functional dependence after minor stroke/TIA with exploratory pharmacogenetic associations: a post-hoc analysis of the INSPIRES trial

Background and purposeDual antiplatelet therapy (DAPT) reduces stroke recurrence after minor stroke/TIA, yet a clinically meaningful proportion of patients remain functionally dependent at 90 days. We developed an interpretable clinical prediction model to define a high-risk subgroup, and separately explored pharmacogenetic associations within this subgroup to generate hypotheses for precision secondary prevention.MethodsIn this post-hoc analysis of the INSPIRES trial (4,439 patients), LASSO logistic regression selected predictors for 90-day functional dependence (mRS > 2). Model performance was assessed by discrimination, calibration, and decision curve analysis. In a genotyped subcohort, CYP1A2 rs762551 and POR rs1057868 were evaluated for outcome association and enrichment in the high-risk subgroup.ResultsLogistic regression achieved the highest AUC point estimate (AUC = 0.727) among

Genetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilities

A Review of Differences Identified in Gut Microbiome Composition Between Young, Old, and Long-Lived Individuals

The gut microbiome changes with age in ways that are not favorable to health. Microbes that provoke inflammation and tissue dysfunction grow in number, replacing those microbes that generate beneficial metabolites. There are many plausible contributions to this process of change, and as is usually the case for anything to do with aging, it is hard to determine which are more or less important than the others. This is particularly the case here, as studies suggest that meaningful change in the composition of the gut microbiome begins as early as the mid-30s, a point in adult life at which very little is concretely known regarding which mechanisms of aging are dominant. The authors of today's open access paper surveyed the literature to identify human studies […]

Low-Fat Vegan Diet Shows Benefits in Type 2 Diabetes

A human trial found that even without caloric restriction, a low-fat, plant-based diet improved blood sugar control, reduced liver fat, and lowered the quantity of advanced glycation end products (AGEs) in the skin [1]. An all-you-can-eat vegan buffet Type 2 […]